Akoya Biosciences Management
Management criteria checks 3/4
Akoya Biosciences' CEO is Brian McKelligon, appointed in Jul 2017, has a tenure of 7.42 years. total yearly compensation is $2.92M, comprised of 18.6% salary and 81.4% bonuses, including company stock and options. directly owns 0.075% of the company’s shares, worth $88.98K. The average tenure of the management team and the board of directors is 2.5 years and 4.4 years respectively.
Key information
Brian McKelligon
Chief executive officer
US$2.9m
Total compensation
| CEO salary percentage | 18.6% |
| CEO tenure | 7.4yrs |
| CEO ownership | 0.08% |
| Management average tenure | 2.5yrs |
| Board average tenure | 4.4yrs |
Recent management updates
Recent updates
Market Cool On Akoya Biosciences, Inc.'s (NASDAQ:AKYA) Revenues Pushing Shares 29% Lower
Dec 14
Revenue Downgrade: Here's What Analysts Forecast For Akoya Biosciences, Inc. (NASDAQ:AKYA)
Nov 19Is Akoya Biosciences (NASDAQ:AKYA) Using Too Much Debt?
Nov 12Akoya Biosciences, Inc. (NASDAQ:AKYA) Stock Rockets 36% But Many Are Still Ignoring The Company
Oct 08Akoya Biosciences, Inc. (NASDAQ:AKYA) Just Reported, And Analysts Assigned A US$5.42 Price Target
Aug 09Market Might Still Lack Some Conviction On Akoya Biosciences, Inc. (NASDAQ:AKYA) Even After 31% Share Price Boost
Jun 27Is Akoya Biosciences (NASDAQ:AKYA) A Risky Investment?
Jun 24We Think Shareholders Are Less Likely To Approve A Large Pay Rise For Akoya Biosciences, Inc.'s (NASDAQ:AKYA) CEO For Now
May 29Investors Continue Waiting On Sidelines For Akoya Biosciences, Inc. (NASDAQ:AKYA)
May 10Is Akoya Biosciences (NASDAQ:AKYA) Weighed On By Its Debt Load?
Feb 28Investors Still Aren't Entirely Convinced By Akoya Biosciences, Inc.'s (NASDAQ:AKYA) Revenues Despite 31% Price Jump
Nov 25Akoya Biosciences Seeks Growth Despite Higher Operating Losses
May 30Akoya Biosciences, Inc. (NASDAQ:AKYA) Just Reported First-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?
May 11CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$58m |
| Jun 30 2024 | n/a | n/a | -US$60m |
| Mar 31 2024 | n/a | n/a | -US$68m |
| Dec 31 2023 | US$3m | US$543k | -US$63m |
| Sep 30 2023 | n/a | n/a | -US$71m |
| Jun 30 2023 | n/a | n/a | -US$76m |
| Mar 31 2023 | n/a | n/a | -US$73m |
| Dec 31 2022 | US$3m | US$518k | -US$71m |
| Sep 30 2022 | n/a | n/a | -US$69m |
| Jun 30 2022 | n/a | n/a | -US$63m |
| Mar 31 2022 | n/a | n/a | -US$51m |
| Dec 31 2021 | US$2m | US$393k | -US$44m |
| Sep 30 2021 | n/a | n/a | -US$34m |
| Jun 30 2021 | n/a | n/a | -US$28m |
| Mar 31 2021 | n/a | n/a | -US$28m |
| Dec 31 2020 | US$516k | US$350k | -US$22m |
| Dec 31 2019 | US$484k | US$333k | -US$18m |
Compensation vs Market: Brian's total compensation ($USD2.92M) is above average for companies of similar size in the US market ($USD646.54K).
Compensation vs Earnings: Brian's compensation has been consistent with company performance over the past year.
CEO
Brian McKelligon (55 yo)
7.4yrs
Tenure
US$2,919,599
Compensation
Mr. Brian McKelligon has been Chief Executive Officer and Director at Akoya Biosciences, Inc. since July 2017 and also serves as its President. Prior to joining Akoya, he led corporate and business develop...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 7.4yrs | US$2.92m | 0.075% $ 89.0k | |
| CFO, Principal Financial Officer & Principal Accounting Officer | 1.8yrs | US$2.37m | 0.092% $ 109.3k | |
| Senior Vice President of Operations | less than a year | no data | no data | |
| Senior Director of Business Development & Investor Relations Strategy | no data | no data | no data | |
| Chief Legal Officer | 1.8yrs | no data | 0.012% $ 14.6k | |
| Chief Business Officer | 4.3yrs | US$365.22k | 0.29% $ 346.1k | |
| Senior Vice President of Research & Development and Laboratory Operations | 3.2yrs | no data | 0.17% $ 197.8k | |
| Secretary | no data | no data | no data |
2.5yrs
Average Tenure
51yo
Average Age
Experienced Management: AKYA's management team is considered experienced (2.5 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 7.4yrs | US$2.92m | 0.075% $ 89.0k | |
| Independent Director | 9.1yrs | US$251.66k | 0.75% $ 883.3k | |
| Independent Director | 3.3yrs | US$237.50k | 0.040% $ 47.8k | |
| Independent Director | 5.3yrs | US$220.00k | 0% $ 0 | |
| Director | 9.1yrs | US$210.00k | 0.47% $ 560.7k | |
| Independent Director | 7.4yrs | US$232.50k | 1.99% $ 2.4m | |
| Member of Scientific Advisory Board | less than a year | no data | no data | |
| Independent Chairman | 3.5yrs | US$250.00k | 0.058% $ 68.1k | |
| Member of Scientific Advisory Board | less than a year | no data | no data | |
| Chair of the Scientific Advisory Board | less than a year | US$220.00k | 1.24% $ 1.5m |
4.4yrs
Average Tenure
66yo
Average Age
Experienced Board: AKYA's board of directors are considered experienced (4.4 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/30 09:41 |
| End of Day Share Price | 2024/12/30 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Akoya Biosciences, Inc. is covered by 10 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Mark Massaro | BTIG |
| Kyle Mikson | Canaccord Genuity |
| Timothy Chiang | Capital One Securities, Inc. |